Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients with Duchenne with a confirmed mutation in the Duchenne gene. The company is also developing SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Catalent Maryland, Inc.; Nationwide Children's Hospital; Dyno Therapeutics; Hansa Biopharma; Duke University; and Genethon. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Sarepta Therapeutics Inc.

Analysts are intrested in these 5 stocks: ( ($VRT) ), ( ($AFRM) ), ( ($SRPT) ), ( ($MU) ) and ( ($PEP) ). Here is a breakdown of their recent


Vertiv, Affirm, Sarepta, Micron, PepsiCo: Trending by Analysts

In a report released today, Uy Ear from Mizuho Securities reiterated a Buy rating on Sarepta Therapeutics, with a price target of $26.00. Ear cover...

Sarepta Therapeutics (SRPT) Gets a Buy from Mizuho Securities

In a report released today, Andreas Argyrides from Oppenheimer maintained a Buy rating on Sarepta Therapeutics, with a price target of $37.00. Argy...

Oppenheimer Reaffirms Their Buy Rating on Sarepta Therapeutics (SRPT)

An announcement from Sarepta Therapeutics ( ($SRPT) ) is now available. On December 7, 2025, Sarepta Therapeutics‘ Board of Directors granted equit...

Sarepta Grants CEO Equity Awards After Eight Years

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Scholar Rock Holding (SRRK – Research Report), Twist...

Current Yield	N/A	Payout Ratio	0.00%
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SRPT	$21.53	-1.01%	2.01M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SRPT	$21.53	-1.0%	2.01M
3
4
5
6

SRPT

SRPT

Dividend Overview

Get Sarepta Therapeutics Inc. Data in Excel

Get Sarepta Therapeutics Inc. Data in Excel